This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Cara (CARA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -25.42% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 4.92% and 1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cara Shares Up on Positive Phase III Data for Itchiness Drug
by Zacks Equity Research
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
by Zacks Equity Research
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?
by Zacks Equity Research
Management at Cooper Companies (COO) expects solid contributions from CVI and CSI units.
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW